Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Viking Therapeutics (VKTX) EBITDA (2016 - 2025)

Historic EBITDA for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$90.2 million.

  • Viking Therapeutics' EBITDA fell 32901.22% to -$90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$238.7 million, marking a year-over-year decrease of 14701.6%. This contributed to the annual value of -$110.4 million for FY2024, which is 2956.02% down from last year.
  • Viking Therapeutics' EBITDA amounted to -$90.2 million in Q3 2025, which was down 32901.22% from -$65.5 million recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' EBITDA peaked at -$12.7 million during Q4 2021, and registered a low of -$90.2 million during Q3 2025.
  • Over the past 5 years, Viking Therapeutics' median EBITDA value was -$19.6 million (recorded in 2023), while the average stood at -$27.4 million.
  • In the last 5 years, Viking Therapeutics' EBITDA surged by 608.51% in 2024 and then crashed by 32901.22% in 2025.
  • Quarter analysis of 5 years shows Viking Therapeutics' EBITDA stood at -$12.7 million in 2021, then tumbled by 48.41% to -$18.9 million in 2022, then dropped by 27.46% to -$24.1 million in 2023, then crashed by 57.07% to -$37.8 million in 2024, then plummeted by 138.52% to -$90.2 million in 2025.
  • Its last three reported values are -$90.2 million in Q3 2025, -$65.5 million for Q2 2025, and -$45.1 million during Q1 2025.